Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial w/ open-label extension (Apeldoorn et al, 2024) adds to previous ketamine findings 25 mar. Escrito por Michael DeMarco https://ketaminetherapypalmsprings.com/ketamine-research-1/oral-esketamine-in-patients-with-treatment-resistant-depression-a-double-blind-randomized-placebo-controlled-trial-w-open-label-extension-apeldoorn-et-al-2024-builds-adds-to-ketamine-findings Michael DeMarco Consultor en Terapias & Prácticas Emergentes en Medicina Psicodélica https://neopsychedelicinstitute.org
Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial w/ open-label extension (Apeldoorn et al, 2024) adds to previous ketamine findings 25 mar. Escrito por Michael DeMarco https://ketaminetherapypalmsprings.com/ketamine-research-1/oral-esketamine-in-patients-with-treatment-resistant-depression-a-double-blind-randomized-placebo-controlled-trial-w-open-label-extension-apeldoorn-et-al-2024-builds-adds-to-ketamine-findings Michael DeMarco Consultor en Terapias & Prácticas Emergentes en Medicina Psicodélica https://neopsychedelicinstitute.org
